What is Marijuana Rescheduling?
For the first time in over five decades, the federal government of the United States has taken a decisive, landmark step in how it classifies marijuana. On April 22–23, 2026, Acting Attorney General Todd Blanche signed a final order under the authority of the Controlled Substances Act (CSA) immediately moving FDA-approved marijuana products and state-licensed medical marijuana from Schedule I — the most restrictive federal drug category — to Schedule III. This action followed President Trump’s December 18, 2025 Executive Order on Increasing Medical Marijuana and Cannabidiol Research, which directed the Drug Enforcement Administration (DEA) and the Department of Justice (DOJ) to move as swiftly as legally possible to complete this historic reclassification. Schedule I substances are defined as having no currently accepted medical use and a high potential for abuse — a category that also includes heroin, LSD, and ecstasy. By contrast, Schedule III substances are those with a moderate to low potential for physical and psychological dependence, placing medical marijuana alongside ketamine, anabolic steroids, and acetaminophen with codeine.
It is critically important to understand exactly what this rescheduling does — and equally what it does not do. The April 2026 DOJ final order does not federally legalize recreational marijuana. Any marijuana that is neither contained in an FDA-approved drug product nor subject to a qualifying state medical marijuana license remains a Schedule I controlled substance, subject to the same administrative, civil, and criminal penalties as before. Synthetic THC and hemp-derived THC products are also unaffected and remain Schedule I. What has changed is profoundly significant for the medical cannabis industry, for researchers, and for the tax landscape of legal cannabis businesses. The DEA simultaneously announced an expedited administrative hearing process — beginning June 29, 2026 — to consider whether all marijuana, including recreational cannabis, should be moved to Schedule III. A final rule from that hearing process could, if completed on the DOJ’s aggressive timeline, be published as soon as late 2026.
Key Marijuana Rescheduling Facts in the US 2026
The following table presents the most important, verified facts surrounding the marijuana rescheduling 2026 action — all drawn from official US government sources and confirmed federal agency releases.
| Fact | Detail |
|---|---|
| Order Effective Date | April 22–23, 2026 |
| Signed By | Acting Attorney General Todd Blanche |
| Authority Used | Single Convention on Narcotic Drugs / CSA §811 |
| Previous Schedule | Schedule I (since 1970) |
| New Schedule (Medical) | Schedule III |
| Triggering Executive Order | EO dated December 18, 2025 |
| Broader Hearing Start Date | June 29, 2026 |
| Hearing Conclusion Target | July 15, 2026 |
| Public Comments Received (2024 Rulemaking) | Over 43,000 |
| FDA-Approved Marijuana Products Covered | 4 products (as of April 2026) |
| States with Medical Marijuana Laws | 40 states + DC, Puerto Rico, Guam, USVI |
| States with Recreational Marijuana Laws | 24 states + DC, Guam, Northern Mariana Islands |
| DEA Registration Deadline (Priority) | June 22, 2026 (60 days from publication) |
| DEA Application Processing Target | 6 months for priority applicants |
| Recreational Marijuana Status | Remains Schedule I |
| Synthetic THC Status | Remains Schedule I |
| Section 280E Relief (Medical Operators) | Effective immediately for state-licensed medical operators |
Source: U.S. Department of Justice Office of Public Affairs, DEA Final Order, April 2026; U.S. Congressional Research Service Report IF12270, March 2026
The sheer breadth of what the April 22, 2026 rescheduling order touches is genuinely staggering when you look at the numbers side by side. For 53 years, from 1970 to 2026, marijuana sat locked in the same federal classification as heroin, despite the reality on the ground shifting dramatically across state legislatures. The fact that over 43,000 formal public comments were submitted during the Biden-era 2024 rulemaking process alone reflects just how deeply invested American patients, businesses, researchers, and advocates are in getting this policy right. The dual-track approach — an immediate partial rescheduling paired with an expedited broader hearing process targeting completion by mid-July 2026 — reflects the Trump administration’s attempt to balance speed with legal compliance. The requirement for state-licensed medical operators to file DEA registration applications by June 22, 2026 to maintain operating continuity while under federal review is a critically practical deadline that thousands of dispensaries across 40 states must now navigate.
Marijuana Rescheduling Timeline in the US 2026
Understanding how the US arrived at this 2026 marijuana rescheduling moment requires tracing a policy evolution that spans administrations, agencies, and decades of shifting science and public opinion.
| Year / Date | Event | Agency / Actor |
|---|---|---|
| 1970 | Marijuana placed on Schedule I under the CSA | U.S. Congress |
| 1996 | California becomes first state to allow medical marijuana | California Legislature |
| October 2022 | President Biden requests HHS/DEA review of marijuana scheduling | Biden Administration |
| August 2023 | HHS recommends rescheduling marijuana to Schedule III | HHS |
| April 2024 | DOJ Office of Legal Counsel validates HHS’s two-part “accepted medical use” test | DOJ OLC |
| May 21, 2024 | DEA publishes Notice of Proposed Rulemaking to reschedule marijuana to Schedule III | DEA |
| August 2024 | DEA receives over 43,000 public comments; announces hearing | DEA |
| August 29, 2024 | Notice of Hearing published in Federal Register | DEA |
| January 2025 | DEA’s administrative law judge postpones hearing pending appeal | DEA ALJ |
| December 18, 2025 | President Trump signs Executive Order directing expedited rescheduling | White House |
| April 22–23, 2026 | Acting AG Blanche signs final order; FDA-approved and state-licensed medical marijuana moved to Schedule III | DOJ / DEA |
| June 22, 2026 | Priority DEA registration deadline for state medical marijuana operators | DEA |
| June 29, 2026 | New expedited DEA administrative hearing begins (broader rescheduling of all marijuana) | DEA |
| July 15, 2026 | Target completion date for broader hearing | DOJ / DEA |
Source: U.S. Department of Justice Press Release, April 23, 2026; Congressional Research Service Report IF12270, March 2026; DEA Federal Register Notices
What this timeline reveals is a policy shift that has been decades in the making, built on a foundation of evolving scientific consensus, state-level experimentation, and persistent bipartisan political pressure. The critical inflection point was the August 2023 HHS recommendation — the first time a federal health agency formally concluded, based on scientific and medical evaluation, that marijuana has a “currently accepted medical use” under the CSA. That scientific determination made the legal path to rescheduling not just possible but arguably inevitable. The Trump administration’s move in December 2025 to issue an executive order — and the DOJ’s subsequent use of its Single Convention treaty authority to bypass the slower full rulemaking process — represents a calculated acceleration that delivered results within four months of the executive order’s signing.
Marijuana Market Size & Economic Impact in the US 2026
The economic dimensions of the marijuana rescheduling 2026 are enormous. The table below captures the current state of the US cannabis market as of early 2026.
| Economic Indicator | Figure | Context |
|---|---|---|
| US Cannabis Market Revenue (2026 projected) | ~$47–49.5 billion | Largest single-country cannabis market globally |
| US Cannabis Market Revenue (2024 actual) | $30.1 billion | First year to face year-over-year decline in legal history |
| US Cannabis Market Revenue (2025 est.) | $29.1–$29.6 billion | First-ever annual revenue decline for US legal market |
| Global Cannabis Market Size (2026) | $137.67 billion | Up from $102.72 billion in 2025 |
| Cannabis Contribution to US Economy (2025) | ~$149 billion | Including direct, indirect, and induced impacts |
| State Cannabis Tax Revenue (2024) | $4.4 billion | Across all legal states combined |
| Medical Marijuana Retail Sales (2026 projected) | $15.6 billion | Up from earlier years as programs mature |
| US Cannabis Industry Jobs (2025) | 425,002 FTE | Down ~15,000 from 2023 peak of 440,445 |
| Global Cannabis Market CAGR (to 2034) | 34.03% | Forecast to reach $1.43 trillion by 2034 |
| California Cannabis Sales (2024) | $4.27 billion | Largest state market |
| Michigan Cannabis Sales (2024) | $3.29 billion | Second largest state market |
| Average Dispensary Budtender Annual Pay (2026) | $30,157 | Reflects maturation of labor market |
| North American Share of Global Cannabis Market | ~83.82% | North America dominates globally |
Source: Whitney Economics 2025 Forecast Update; Statista Cannabis Market Outlook 2026; Flowhub Cannabis Industry Statistics 2026; NIDA Fiscal Year 2024 Budget
The economic picture that emerges from this data is one of a maturing, consolidating industry that is simultaneously facing the most significant regulatory tailwind of its existence. The unprecedented year-over-year revenue decline of the US legal market in 2025 — falling below the $30.1 billion mark achieved in 2024 — reflects the brutal pricing compression and competition that mature markets like California, Illinois, and Arizona have experienced. Yet with Schedule III reclassification now effective for medical cannabis, the elimination of Section 280E tax liability is expected to immediately inject profitability back into hundreds of state-licensed medical operators who previously could not deduct ordinary business expenses like rent, payroll, or marketing from their federal taxes. The projection of a $47–49.5 billion US cannabis market for 2026 — representing a dramatic recovery — is largely predicated on this 280E relief and the downstream effects of improved operator financial health, increased banking access, and renewed investor confidence.
Section 280E Tax Impact of Marijuana Rescheduling in the US 2026
Perhaps the single most consequential immediate financial impact of the April 2026 rescheduling order is on federal taxation. Section 280E of the Internal Revenue Code has been a crippling burden on cannabis businesses for decades.
| Tax Factor | Before Rescheduling (Schedule I) | After Rescheduling (Schedule III, Medical) |
|---|---|---|
| Section 280E Applicability | Fully applied — no business expense deductions | Eliminated for state-licensed medical operators |
| Deductible Expenses | None (only COGS deductible) | Rent, payroll, marketing, overhead — all standard deductions permitted |
| Effective Federal Tax Rate for Cannabis Cos. | Often 70%+ effective rate | Normalized corporate rates (21% C-Corp) |
| IRS/Treasury Guidance | None for cannabis | Guidance announced April 2026 — transition rules in progress |
| Retroactive Relief | N/A | AG Blanche encouraged Treasury to consider retroactive 280E relief |
| Application to Recreational Operators | Applies | Still applies — recreational remains Schedule I |
| Application to Dual-License Operators | Full 280E | Partial — medical portion exempt; guidance awaited |
| Michigan State Excise Tax (2026) | 24% wholesale excise tax | State-level burdens unchanged by federal rescheduling |
| IRS Transition Rule | N/A | Rescheduling applies for full taxable year including April 22, 2026 |
Source: U.S. Department of the Treasury and IRS Press Release, April 2026; DOJ Final Order April 22, 2026; Congressional Research Service IF12270, March 2026
The elimination of Section 280E for state-licensed medical marijuana operators is what industry insiders and legal analysts have called the “Great Normalization” — the moment legal cannabis finally gets treated like any other legitimate American business for tax purposes. For years, operators in this industry were simultaneously asked to comply with state regulatory frameworks and pay taxes like businesses, yet were denied the fundamental right to deduct their business expenses. The DOJ’s April 2026 final order expressly confirms that state licensees are no longer subject to the 280E deduction disallowance. The Treasury Department and the IRS announced in April 2026 that they are preparing guidance on transition rules, including the critical question of whether relief will be retroactive to prior tax years in which operators held valid state medical marijuana licenses. This retroactive relief question — which the AG actively encouraged the Treasury Secretary to consider — could translate into billions of dollars in refund claims for medical cannabis operators across 40 states.
State-Level Marijuana Legalization Landscape in the US 2026
The state-by-state reality of marijuana legalization in America provides essential context for understanding the scope of the 2026 rescheduling order.
| Category | Number of Jurisdictions | Examples / Notes |
|---|---|---|
| Medical Marijuana (Comprehensive) | 40 states + DC, PR, Guam, USVI | Covers FDA-recognized and state-licensed medical programs |
| Recreational / Adult-Use Marijuana | 24 states + DC, Guam, N. Mariana Islands | Adults 21+ may legally possess and purchase |
| Limited-Access Medical (Low-THC / CBD Only) | 8 states | Iowa, Georgia — only limited-access programs |
| No Medical or Recreational Access | 3 jurisdictions | Idaho, Kansas, American Samoa |
| States with No Recreational, Active 2026 Reform Bills | Several | Texas, Pennsylvania, Hawaii, Wisconsin — active campaigns |
| Americans Living in State with Any Cannabis Access | 74% | Medical or recreational legal |
| Americans Living in County with ≥1 Dispensary | 79% | Nearly 4 in 5 Americans have dispensary access |
| Total US Dispensaries (2026) | ~15,000 | Nationwide, across all legal states |
| States Likely to Legalize Next (2026) | Pennsylvania, Hawaii, Wisconsin, New Hampshire | Active campaigns, polling support |
| 2026 November Ballot States (Reform Measures Filed) | 9 states | As of March 2026 |
| States Where Youth Cannabis Use Declined Post-Legalization | 19 of 21 states | Per state-reported data |
Source: Congressional Research Service Report IF12270, March 2026; Marijuana Policy Project 2026 Policy Reform Tracker; Congress.gov
The 40-state medical marijuana reality is precisely what made the DOJ’s April 2026 rescheduling action legally sustainable and practically necessary. Acting Attorney General Blanche explicitly acknowledged in the order that the action “recognizes the longstanding regulation of medical marijuana by state governments and the need for a common-sense approach to this reality.” The gap between federal Schedule I classification and the on-the-ground operation of tens of thousands of state-licensed medical cannabis businesses had simply become untenable. The statistic that 79% of Americans now live in a county with at least one legal cannabis dispensary means that marijuana has, for most Americans, already been a regulated commercial reality for years — the federal government’s Schedule III action simply acknowledges what communities across the country already knew. The fact that youth cannabis use has declined in 19 of 21 states that have legalized since 2014 directly contradicts one of the most persistent arguments against legalization — that it would increase access and use among teenagers.
Marijuana Usage & Public Opinion Statistics in the US 2026
Public support for marijuana rescheduling and broader legalization has reached historic highs, and usage data confirms marijuana’s status as the most widely used federally controlled substance in the United States.
| Statistic | Figure |
|---|---|
| Americans Who Used Marijuana in Past Year (age 12+) | 64.2 million |
| Americans Who Used Marijuana in Past Month | 44.3 million |
| Percentage of Americans 12+ Who Used Marijuana (Past Month, 2024) | 15.4% |
| Percentage of Americans 12+ Who Used Marijuana (Past Month, 2008) | 6.1% |
| Americans Who Have Ever Tried Marijuana | ~47% |
| Active Marijuana Users (Gallup, 2023–2024 combined) | 15% |
| Youth (12–17) Past-Month Marijuana Use (2024) | 6.0% |
| Americans Who Support Marijuana Legalization (Medical + Recreational) | ~57–60% |
| Americans Who Support Medical Marijuana Legalization Only | ~32–33% |
| Americans Who Believe Cannabis Stigma Has Diminished | 64% |
| Americans Who Consider Alcohol More Harmful Than Marijuana | 72% |
| Most Common Reason for Medical Cannabis Use | Trouble Sleeping (65%) |
| Second Most Common Reason | Chronic Pain (50%) |
| Americans Who Consume Cannabis (Women 21+) | More than 1 in 3 |
Source: National Survey on Drug Use and Health (NSDUH) 2024; Pew Research Center 2024; Gallup 2024; Congressional Research Service IF12270, March 2026
📈 MARIJUANA PAST-MONTH USE TREND (% of Americans 12+, 2008–2024)
2008: ████░░░░░░░░░░░░░░░░ 6.1%
2012: ██████░░░░░░░░░░░░░░ 8.3%
2016: ███████████░░░░░░░░░ 10.6%
2019: █████████████░░░░░░░ 12.6%
2021: ██████████████░░░░░░ 13.5%
2023: ███████████████░░░░░ 15.1%
2024: ████████████████░░░░ 15.4% ◄ ALL-TIME HIGH
────────────────────────────────────────
0% 5% 10% 15%
The NSDUH 2024 data paints a picture of marijuana’s transformation from a fringe behavior into a mainstream American experience. 64.2 million Americans — more than the entire population of California and New York combined — used marijuana in the past year as of 2024. That figure represents the highest ever recorded in NSDUH history, and the trajectory from 6.1% monthly use in 2008 to 15.4% in 2024 tracks almost perfectly with the wave of state-level legalization that swept the country over that same period. Most tellingly, the demographic driving this growth is not just young people — it’s adults across age groups, including women (now more than 1 in 3 of women over 21) and older adults. The 57–60% public support for full legalization, combined with the near-universal support for medical marijuana use, means that the April 2026 rescheduling action aligns with where American public opinion has been heading for over a decade. The finding that 72% of Americans consider regular alcohol consumption more harmful than habitual marijuana use underscores just how dramatically public perception has shifted since the days of “Reefer Madness.”
DEA Registration & Regulatory Impact on Medical Cannabis Operators in the US 2026
The April 2026 rescheduling order doesn’t just change marijuana’s drug schedule — it creates an entirely new federal regulatory framework that state-licensed medical cannabis operators must now navigate.
| Regulatory Element | Requirement / Impact |
|---|---|
| DEA Registration Requirement | All state-licensed medical marijuana manufacturers, distributors, and dispensers must register with the DEA |
| State License as Federal Authorization | State medical marijuana credentials accepted as conclusive evidence of state-law authorization |
| Priority Application Deadline | June 22, 2026 (60 days from order publication) |
| DEA Processing Timeline (Priority Apps) | Target of 6 months |
| Grounds for Denial | Inconsistency with public interest (21 U.S.C. §823) or Single Convention requirements |
| Automatic Registration Suspension | Registration suspends if state license is suspended, revoked, or expires |
| New Compliance Obligations | Schedule III recordkeeping, reporting, security standards, and labeling requirements |
| Synthetic THC / Recreational Marijuana | Unchanged — remains Schedule I; no DEA registration pathway |
| Existing FDA-Approved Products Covered | 4 marijuana-containing FDA-approved products (as of April 2026) |
| DOT Drug Testing Policy | Unchanged — DOT not required to change marijuana prohibition policy |
| ADA Implications (Employers) | Increased employee ADA accommodation claims expected for medical marijuana use |
| Single Convention Crop Purchase Mechanism | Manufacturers must prepare for nominal-price crop purchase under treaty obligations |
Source: DOJ Final Order effective April 22, 2026; Foley & Lardner Legal Analysis; U.S. Department of Justice Office of Public Affairs
The creation of a fast-track DEA registration pathway that directly leverages existing state licensing infrastructure is one of the most practically significant elements of the April 2026 order. For the first time, a state medical marijuana license is not just a state-law permission — it is, by explicit federal recognition, the foundation of a legitimate federal DEA registration. The deadline of June 22, 2026 for priority applications means that qualifying operators across 40 states have a narrow but critical window to secure their federal registration and maintain operating continuity during the DEA’s review. Operators who miss this window do not lose their ability to register but do lose the guaranteed right to keep operating under their state license during the pendency of review. The new Schedule III compliance obligations — covering recordkeeping, security, labeling, and reporting — will require many medical dispensaries to upgrade their operational systems, particularly those that have operated solely under state regulatory frameworks with minimal federal oversight until now.
Cannabis Research Impact of Marijuana Rescheduling in the US 2026
One of the most consistently cited justifications for moving marijuana to Schedule III is the dramatic expansion it will enable in federally sanctioned medical research.
| Research Factor | Before Rescheduling (Schedule I) | After Rescheduling (Schedule III) |
|---|---|---|
| DEA Registration for Researchers | Required; historically slow and burdensome | Still required but significantly streamlined |
| Marijuana Source for Research | Only DEA-registered sources (previously a federal monopoly) | State-licensed entities now accessible as sources |
| FDA IND Application | Required for all marijuana research | Required for clinical trials; reduced friction |
| Barriers to Entry for New Researchers | Very high — Schedule I oversight demands | Materially reduced under Schedule III |
| NIDA Research Budget (FY2024) | ~$1.663 billion (total, including cannabis-related research) | Expected to expand with rescheduling signal |
| FDA-Approved Marijuana-Based Drugs | 4 products (Epidiolex, Marinol generics, Syndros, Cesamet) | Same 4, but rescheduling eases pathway for new approvals |
| Conditions Under Active Research (Pre-Rescheduling) | PTSD, epilepsy, chronic pain, chemotherapy nausea | Expanded clinical pipeline expected |
| Research Barrier Addressed by HALT Fentanyl Act (P.L. 119-26) | Streamlined Schedule I research (including marijuana) | Further reduced by Schedule III move |
| Medical Marijuana and Cannabidiol Research Expansion Act | DEA required to expedite researcher registrations | Now reinforced by Schedule III status |
| Public Health Reporting Requirements (HHS) | Therapeutic potential of marijuana for epilepsy, adolescent brain effects, driving impairment | Ongoing, accelerated by rescheduling |
Source: Congressional Research Service IF12270, March 2026; National Institute on Drug Abuse FY2024 Congressional Budget Justification; U.S. Department of Justice April 2026 Press Release
🔬 CANNABIS RESEARCH ACCESS: BEFORE vs AFTER RESCHEDULING 2026
BEFORE (Schedule I): AFTER (Schedule III):
───────────────────── ────────────────────────
DEA Registration ✓ (slow) DEA Registration ✓ (faster)
FDA IND Required ✓ FDA IND Required ✓
Federal Source Only ✓ State-Licensed Sources ✓ (NEW)
High entry barrier Lower entry barrier
Limited researcher pool Expanded researcher access
4 FDA-approved drugs Pathway eased for more approvals
$1.663B NIDA budget Expected budget growth
The research implications of Schedule III reclassification may prove to be the most enduring and consequential dimension of the 2026 marijuana rescheduling — even more so than the immediate tax relief or regulatory changes. For decades, the Schedule I status of marijuana created a paradox: researchers needed federally sanctioned marijuana to study it, but access to federally sanctioned marijuana required DEA registration, which was deliberately difficult to obtain. The result was that the country with the world’s largest cannabis market had one of the most restrictive environments for scientifically studying the plant’s medical potential. With Schedule III status now in effect for medical marijuana, and with the Medical Marijuana and Cannabidiol Research Expansion Act already mandating expedited DEA researcher registrations, the barriers that kept well-funded pharmaceutical and academic researchers out of the cannabis science space have been materially reduced. The four FDA-approved marijuana-containing products currently on the market — Epidiolex (CBD for epilepsy), Marinol, Syndros (synthetic THC for chemotherapy nausea), and Cesamet — represent just the beginning of what the pharmaceutical pipeline could deliver once research conditions normalize under Schedule III.
Broader Rescheduling Hearing & What Comes Next in the US 2026
The April 2026 order is only the first chapter. The real story continues with the June 29, 2026 DEA administrative hearing that will determine whether all marijuana — including recreational and unlicensed cannabis — moves to Schedule III.
| Milestone | Date / Detail |
|---|---|
| DEA Prior Hearing Withdrawn | Biden-era hearing terminated by DEA in April 2026 |
| New Federal Register Notice Published | April 2026 — governs new hearing proceedings |
| New Hearing Start Date | June 29, 2026 |
| Hearing Completion Target | July 15, 2026 |
| Scope of New Hearing | Broader rescheduling of all marijuana — including recreational |
| Expected Final Rule Publication | Late 2026 (if proceedings stay on track) |
| Litigation Risk | Opponents expected to challenge; could extend timeline |
| SAFER Banking Act Status | Stalled in Senate; cannabis banking reform ongoing in Congress |
| Hemp-Derived THC Threshold Change | November 2025 legislation changes thresholds, effective November 2026 |
| If Broader Rescheduling Completes | 280E relief, banking access, research expansion extends to recreational cannabis |
| DEA Administrator Statement | “Expeditiously moving forward… bringing consistency and oversight to an area that has lacked both” — DEA Administrator Terry Cole |
| Congressional Action Possible | Congress could pass legislation (MORE Act, SAFER Banking) independently of DEA rulemaking |
Source: U.S. Department of Justice Press Release April 23, 2026; Foley Hoag LLP Legal Analysis April 2026; Marijuana Policy Project 2026 Policy Reform Tracker
The June 29, 2026 hearing represents the true inflection point for the broader US cannabis industry — including the 24-state recreational market that currently generates the majority of cannabis revenue but remains completely outside the protection of the April 2026 order. If the DEA completes the broader rescheduling on its aggressive timeline and a final rule is published by late 2026, the full $47–49 billion US cannabis market would gain access to the same 280E tax relief, improved banking access through the SAFER Banking Act, and normalized federal research frameworks that medical operators are already beginning to enjoy. The DEA Administrator Terry Cole’s explicit statement about “bringing consistency and oversight to an area that has lacked both” signals that this administration views completing the broader rescheduling not as an ideological concession but as a regulatory rationalization of a market reality that federal policy can no longer credibly ignore. For industry operators, investors, researchers, patients, and advocates alike, 2026 is the year American marijuana policy finally started catching up to American marijuana reality.
Disclaimer: The data research report we present here is based on information found from various sources. We are not liable for any financial loss, errors, or damages of any kind that may result from the use of the information herein. We acknowledge that though we try to report accurately, we cannot verify the absolute facts of everything that has been represented.
